Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,408.50
(
-1.24%
)
US TECH 100
28,244.40
(
-1.90%
)
Dow Jones
49,526.17
(
-1.07%
)
Brent Oil
106.70
(
0.00%
)
Bitcoin
78,148.42
(
0.00%
)
News Focus
News Focus
Post# of 257580
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122988
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: None

Sunday, 12/09/2007 10:56:16 AM

Sunday, December 09, 2007 10:56:16 AM

Post# of 257580
Anticoagulant Index

Rivaroxaban
#msg-25147464 Rivaroxaban bests Lovenox in VTE prevention
#msg-24337258 Bayer plans 50,000(!)-patient study

Apixaban
#msg-19134406 PFE, BMY ink $1B collaboration
#msg-21044973 Apixaban non-inferior to Warfarin in phase-2

Dabigatran
#msg-25152872 BI starts phase-2 in ACS
#msg-21155926 Dabigatran non-inferior to Lovenox in VTE prevention

Arixtra
#msg-10569101 Arixtra bests Lovenox in ACS

M118
#msg-24457684 M118 has big sales potential
#msg-23604134 MNTA starts phase-2 in ACS
#msg-19617749 Start of phase-1 using sub-Q formulation
#msg-25147975 M118 vs oral FXa inhibitors

General
#msg-18759853 Overview of the new oral anticoagulants

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today